The following secondary endpoints were significantly lower in the CoQ10 group compared with the placebo group : cardiovascular mortality ( 9 % vs. 16 % , p = 0.026 ) , all-cause mortality ( 10 % vs. 18 % , p = 0.018 ) , and incidence of hospital stays for HF ( p = 0.033 ) .